Audience: Clinicians. Published 18 November 2026 (AEDT).

Orforglipron (Foundayo, Eli Lilly), a non-peptide oral GLP-1 receptor agonist, was entered on the ARTG on 16 November 2026 (S4, black triangle). Indications: chronic weight management as an adjunct to diet and physical activity in adults with BMI ≥30 kg/m², or ≥27 to <30 kg/m² with at least one weight-related comorbidity; and insufficiently controlled type 2 diabetes, as monotherapy when metformin is inappropriate or added to other agents. It is not PBS listed.

Evidence

ATTAIN-1 (NEJM 2025) randomised 3,127 adults without diabetes (mean BMI 37) to 6, 12 or 36 mg capsules or placebo for 72 weeks. Treatment-regimen estimand: −7.5%, −8.4% and −11.2% versus −2.1%. At 36 mg, 54.6% lost ≥10% (placebo 12.9%) and 36.0% lost ≥15% (5.9%). In ATTAIN-2 (type 2 diabetes, n=1,613; US label data), the top dose gave −9.6% versus −2.5%. The US label expresses these trial doses as 5.5, 9 and 17.2 mg tablet equivalents.

Pooled harms at the top dose: nausea 35% (placebo 10%), vomiting 24% (4%), constipation 24% (9%); discontinuation for adverse events 10% (3%). Hypoglycaemia (<3.0 mmol/L) occurred in 2% versus 0.2% in ATTAIN-2.

Practical points

It can be taken with or without food. US labelling uses monthly titration from 0.8 mg to a maximum of 17.2 mg daily, CYP3A4 interaction limits, sulfonylurea or insulin dose review, and backup contraception for 30 days after starting and each dose increase with oral contraceptives. Check the Australian PI once it is published.

Limitations

Industry-funded, 72-week trials; no cardiovascular outcome data or head-to-head comparison with injectables; up to 24% missing week-72 weight data. The NEJM full text was not accessible; figures were cross-checked against the US label.

Prepared with AI assistance from the linked sources; not individually reviewed by a clinician. General information only, not individual medical advice.

Sources

Therapeutic Goods Administration: ARTG entry 521942, FOUNDAYO orforglipron 17.2 mg film coated tablet, ARTG date 16 November 2026 (accessed 18 November 2026, AEDT).
Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806 (accessed 18 November 2026, AEDT).
US prescribing information: FOUNDAYO (orforglipron) tablets, DailyMed (accessed 18 November 2026, AEDT).
RACGP newsGP: New oral GLP-1 to hit Australian shelves within days, 17 November 2026 (accessed 18 November 2026, AEDT).